KDC-MN-133 – Kodiac biolabs

Plain-language summaryIntrigue 72 / 100

Dulaglutide, sold as Trulicity, is a once-weekly GLP-1 receptor agonist constructed as an Fc-fusion protein for extended half-life. FDA-approved for type 2 diabetes and cardiovascular risk reduction. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

44/100

Solid first-generation weekly GLP-1 RA now clearly superseded by semaglutide and tirzepatide

Look, dulaglutide is a well-made drug. The IgG4-Fc fusion strategy for extending GLP-1(7-37) half-life to roughly 5 days was genuinely smart engineering in the early 2010s, and the REWIND cardiovascular outcomes trial gave us clean MACE data in a T2DM population with CV risk factors. That’s real science done properly. FDA approval in 2014, multiple large phase 3 programs, solid PK characterization. On evidence quality and translational signal, dulaglutide earns its marks.

Here’s the thing though: we’re rating research interest in 2026, not 2014. And the honest answer is that dulaglutide has been lapped. Semaglutide outperforms it on HbA1c reduction, weight loss, and CV outcomes. The SUSTAIN and STEP programs made dulaglutide look like the warm-up act. Then tirzepatide showed up with dual GIP/GLP-1 agonism and made semaglutide look cautious. From a differentiation standpoint, dulaglutide is now clearly the third option in a class where the top two have eaten most of the interesting research territory.

The mechanism itself, single GLP-1R agonism via a modified peptide sequence, is about as well-understood as any pharmacological target gets. Thats a weakness when youre trying to identify high-value research targets. The FcRn recycling angle is genuinely interesting from a drug-engineering perspective, and investigators working on Fc fusion biology might find dulaglutide useful as a reference construct, but thats a narrow specialty use case. Its not a probe for anything that semaglutide or a purpose-built research tool couldnt address better.

We also think the novelty ceiling here is just low. The GLP-1 receptor agonist class is decades old at this point. Dulaglutide didnt introduce a new mechanism, a new indication, or a new pharmacological insight. It refined the delivery profile, which is a formulation win, not a biology win. For a bench investigator building a research program, there’s very little that dulaglutide lets you ask that you couldnt ask with a better compound.

Where it still earns credit: if your program specifically needs a once-weekly GLP-1 RA with extensive CV outcomes literature and you want something other than semaglutide as a reference comparator, dulaglutide is fully characterized and well-sourced. The REWIND data set is genuinely good. But as an object of primary research interest, the score reflects a compound that did its job and got surpassed. Solid evidence, real translational signal, and an execution story that just doesnt stand out anymore.

Novelty: 30
Mechanism promise: 38
In-category differentiation: 22
Evidence quality: 75
Translational signal: 72
Research bench value: 35

Rationale Dulaglutide scores well on evidence and translational signal thanks to REWIND and large phase 3 RCTs, but novelty and differentiation are badly hurt by semaglutide’s dominance and tirzepatide’s dual-agonism story; the Fc-fusion engineering that was clever in 2014 is just background noise now. Overall lands in the low 40s because the compound is real and well-evidenced but offers a bench investigator almost nothing that a better GLP-1 tool doesn’t already provide.

Weekly GLP-1 Fc fusion

A GLP-1 analog fused to human IgG4 Fc for weekly dosing, FDA-approved as Trulicity for T2DM.

Abstract

Dulaglutide (Trulicity; CAS 923950-08-7; molecular weight ~63000) is an IgG4-Fc fusion protein containing two modified GLP-1(7-37) sequences. The Fc fusion provides extended half-life of approximately 5 days through neonatal Fc receptor recycling, supporting once-weekly subcutaneous dosing. The compound was developed by Eli Lilly and approved by the FDA in 2014 for T2DM. Approved doses are 0.75 to 4.5 mg weekly. The cardiovascular outcomes program (REWIND) demonstrated MACE reduction in T2DM patients with cardiovascular risk factors.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-133Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-133

Dulaglutide

Abstract

Read the full monograph